US 2026/0159563 A1 · USE OF CCL11

Abstract

The disclosure relates to the technical field of vaccine preparation, and in particular to an immune-enhancing delivery system formed by targeted antigen delivery by CCL11. The system further enhances immunogenicity by fusing a chemokine CCL11 with a corresponding antigen molecule, and adding a T2 label at a terminal of the antigen molecule. The system can be a nucleic acid vector or a fusion protein or the like to be applied to prevention and/or treatment of diseases caused by a corresponding antigen. According to the present invention, by utilizing a chemotactic binding capacity of CCL11 with a surface receptor of an immune cell such as a DC, different antigen proteins are transported to the surface of the DC, so that the efficiency of phagocytosis, processing and presentation of the DC on various antigen proteins is improved, and the effect of preventing and treating related diseases is improved.

Claims12

Dependent claims

A method for improving antigen presentation effect, comprising administering to a subject in need thereof at least one of I)-VI),

I) a T2 fragment with an amino acid sequence set forth in SEQ ID NO:
4;
II) chemokine CCL11;
III) a fragment being more than 80% homologous with and functionally identical or similar to I) or II);
IV) a nucleic acid molecule encoding I) or II);
V) a nucleic acid molecule that is derived from the nucleotide sequence of the nucleic acid molecule in IV) by deletion, addition or substitution of one or more nucleotides and encode a protein functionally identical or similar to the nucleic acid molecule in IV);
and
VI) a nucleic acid molecule fully or partially complementary to V).

5 more elements

Dependencies are inferred from the claim text.

Use of ccl11

Life of this patent

Use of ccl11

Life of this patent

Abstract

Claims12